Boai NKY Pharmaceuticals Ltd (300109) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Boai NKY Pharmaceuticals Ltd (300109) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥139.46 Million ≈ $20.41 Million USD) by net assets (CN¥3.69 Billion ≈ $540.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Boai NKY Pharmaceuticals Ltd (300109) total market value for the company's overall valuation and market capitalisation.
Boai NKY Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Boai NKY Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Boai NKY Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boai NKY Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore Boai NKY Pharmaceuticals Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
|
-0.007x |
|
Kerjaya Prospek Group Bhd
KLSE:7161
|
0.003x |
|
BJs Restaurants Inc
NASDAQ:BJRI
|
0.115x |
|
JK Tyre & Industries Limited
NSE:JKTYRE
|
0.143x |
|
Aegean Airlines S.A.
AT:AEGN
|
0.357x |
|
Meitav Dash Investments Ltd
TA:MTDS
|
0.074x |
|
Wangneng Environment Co Ltd
SHE:002034
|
0.073x |
|
Jiuzhitang Co Ltd
SHE:000989
|
0.027x |
Annual Cash Flow Conversion Efficiency for Boai NKY Pharmaceuticals Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Boai NKY Pharmaceuticals Ltd from 2007 to 2025. View today's stock price for Boai NKY Pharmaceuticals Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.66 Billion ≈ $534.86 Million |
CN¥338.11 Million ≈ $49.48 Million |
0.093x | +30.34% |
| 2024-12-31 | CN¥3.61 Billion ≈ $527.92 Million |
CN¥256.03 Million ≈ $37.47 Million |
0.071x | -48.84% |
| 2023-12-31 | CN¥3.52 Billion ≈ $515.09 Million |
CN¥488.25 Million ≈ $71.45 Million |
0.139x | +71.74% |
| 2022-12-31 | CN¥3.12 Billion ≈ $456.15 Million |
CN¥251.77 Million ≈ $36.84 Million |
0.081x | +532.17% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.55 Million |
CN¥43.44 Million ≈ $6.36 Million |
0.013x | -85.27% |
| 2020-12-31 | CN¥3.08 Billion ≈ $450.15 Million |
CN¥266.87 Million ≈ $39.05 Million |
0.087x | +232.53% |
| 2019-12-31 | CN¥3.05 Billion ≈ $446.69 Million |
CN¥79.64 Million ≈ $11.65 Million |
0.026x | -31.79% |
| 2018-12-31 | CN¥1.28 Billion ≈ $186.75 Million |
CN¥48.81 Million ≈ $7.14 Million |
0.038x | +5.36% |
| 2017-12-31 | CN¥1.30 Billion ≈ $190.58 Million |
CN¥47.28 Million ≈ $6.92 Million |
0.036x | -60.99% |
| 2016-12-31 | CN¥1.23 Billion ≈ $179.49 Million |
CN¥114.14 Million ≈ $16.70 Million |
0.093x | +68.78% |
| 2015-12-31 | CN¥1.16 Billion ≈ $170.16 Million |
CN¥64.12 Million ≈ $9.38 Million |
0.055x | -52.64% |
| 2014-12-31 | CN¥400.25 Million ≈ $58.57 Million |
CN¥46.60 Million ≈ $6.82 Million |
0.116x | +89.44% |
| 2013-12-31 | CN¥377.06 Million ≈ $55.18 Million |
CN¥23.17 Million ≈ $3.39 Million |
0.061x | +8.28% |
| 2012-12-31 | CN¥363.81 Million ≈ $53.24 Million |
CN¥20.65 Million ≈ $3.02 Million |
0.057x | +405.33% |
| 2011-12-31 | CN¥350.93 Million ≈ $51.35 Million |
CN¥3.94 Million ≈ $576.77K |
0.011x | -62.77% |
| 2010-12-31 | CN¥333.21 Million ≈ $48.76 Million |
CN¥10.05 Million ≈ $1.47 Million |
0.030x | -93.44% |
| 2009-12-31 | CN¥62.14 Million ≈ $9.09 Million |
CN¥28.57 Million ≈ $4.18 Million |
0.460x | +593.63% |
| 2008-12-31 | CN¥43.93 Million ≈ $6.43 Million |
CN¥-4.09 Million ≈ $-598.80K |
-0.093x | -117.36% |
| 2007-12-31 | CN¥17.82 Million ≈ $2.61 Million |
CN¥9.56 Million ≈ $1.40 Million |
0.536x | -- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP) series products, vinyl methyl ether/maleic anhydride copolymer (PVM/MA, Euroster) copolymer, and oral care products; and medical technology services, such as early tumor screening, molecular diagnostics, and precisio… Read more